Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanc...
Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China
About this item
Full title
Author / Creator
He, Chaoneng , Mi, Xiufang , Xu, Gaoqi , Xu, Xinglu , Xin, Wenxiu , Zhong, Like , Zhu, Junfeng , Shu, Qi , Fang, Luo and Ding, Haiying
Publisher
United States: Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: Public Library of Science
Subjects
More information
Scope and Contents
Contents
We aimed to investigate the cost-effectiveness of tislelizumab plus chemotherapy compared to chemotherapy alone as a first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (OSCC).
A partitioned survival model was developed to evaluate the cost-effectiveness of tislelizumab plus chemotherapy versus chemotherapy alone...
Alternative Titles
Full title
Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_3069288067
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_3069288067
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0302961
